Across TCGA pan-cancer cohorts, CYP46A1 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CYP46A1 data layer compared with 26 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CYP46A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP46A1 expression acts as an unfavorable survival marker.
GBM are the cancer types where CYP46A1 mass-spec protein most reproducibly stratifies survival.